FindTrial
Sign In

Study of two medicines to stop vomiting caused by strong chemotherapy

A Randomized open label Study Comparing the Efficacy of Aprepitant-Olanzapine Versus Netupitant-Palonosetron Therapy for Controlling CINV in Patients Receiving Highly Emetogenic Chemotherapy - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/098653
Enrollment
100
Registered
2025-12-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Intervention1: Aprepitant + Olanzapine: Aprepitant 125 mg orally on Day 1, followed by 80 mg orally on Days 2 3, plus Olanzapine 5 mg orally once daily on Days 1 4, administered as pre-medication befo

Sponsors

Pharmacology Department Paraclinical Block Dr RPGMC Kangra at Tanda HP India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Willing adult patient giving written informed consent. Normal routine blood investigations

Exclusion criteria

Exclusion criteria: Patient not willing to give written informed consent. Pregnant and Lactating females. Patient already on treatment with study drug. Patients with known contraindication or refractoriness to study drugs.

Design outcomes

Primary

MeasureTime frame
Complete Response (CR) to antiemetic therapy, defined as no vomiting and no use of rescue medication during: Acute phase (0 24 hours) after chemotherapy Delayed phase (24 120 hours) after chemotherapyTimepoint: Baseline, 24 hours, and 120 hours after chemotherapy in first cycle.—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDr Atal Sood

Dr Rajendra Prasad Govt Medical College

Atalsood7@gmail.com9418063191

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026